Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.40 |
| ▸ | BMP1 | P13497 | 2/20 | 0.38 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22111148 | 1.00 | GLO1 (0.49) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL29050824 | 0.97 | PTGS1 (0.51) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL2804509 | 0.97 | PTGS1 (0.51) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL29350792 | 0.95 | GLO1 (0.48) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL6863985 | 0.94 | GLO1 (0.47) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL6863991 | 0.94 | GLO1 (0.47) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL29742944 | 0.90 | FOLH1 (0.47) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL31479995 | 0.90 | FOLH1 (0.47) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL30974057 | 0.88 | GLO1 (0.45) | GLO1PTGS1GSTK1BMP1KEAP1 | |
| SCHEMBL30662555 | 0.88 | GLO1 (0.45) | GLO1PTGS1GSTK1BMP1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034090-A1 | CANNABINOID PRODRUG COMPOUNDS | FIRSTLIGHT PHARMACEUTICALS LLC (US) | 2026-02-05 | — | — | US | claimed |
| US-20260034090-A1 | CANNABINOID PRODRUG COMPOUNDS | FIRSTLIGHT PHARMACEUTICALS LLC (US) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034090-A1 | CANNABINOID PRODRUG COMPOUNDS | CNR1, CNR2, FAAH | GLO1 3102/4885PTGS1 1148/4885GSTK1 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.